Vertex Reports First Qtr 2010 Total Revenues OF $22.4 Million (Financial Report‪)‬

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), Cambridge, Mass., has provided an update on recent progress in its development programs in hepatitis C virus (HCV) infection, cystic fibrosis (CF) and other diseases and reported consolidated financial results for the quarter ended March 31, 2010. "Vertex continues to make important advancements across the business as we prepare to submit a New Drug Application for telaprevir in the second half of 2010. Vertex continues to make important advancements across the business as we prepare to submit a New Drug Application for telaprevir in the second half of 2010," said Matthew Emmens, Chairman, President and Chief Executive Officer of Vertex Pharmaceuticals. "Our Phase 3 registration program for telaprevir in hepatitis C virus infection is nearing completion, and this quarter, we expect to receive the first Phase 3 SVR registration data from the ADVANCE trial in treatment-naive patients, followed by additional Phase 3 SVR registration data from the REALIZE trial in treatment-failure patients in the third quarter," continued Mr. Emmens. "Importantly, we now plan to submit our NDA for telaprevir on a rolling basis beginning this summer and expect to complete the NDA submission in the second half of 2010 with clinical data from Phase 3 trials in both treatment-naive and treatment-failure patients. Our commercial and launch preparation activities remain a key focus for 2010, and we are on track to achieve important milestones in the NDA submission process.